Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?

Abstract Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced...

Full description

Saved in:
Bibliographic Details
Published inMolecular medicine (Cambridge, Mass.) Vol. 26; no. 1; pp. 1 - 80
Main Authors Namsolleck, Pawel, Moll, Gert N.
Format Journal Article
LanguageEnglish
Published New York BioMed Central 17.08.2020
BMC
Subjects
ACE2
Angiotensin
ARDS
AT1R
AT2R
Blood pressure
Coronaviruses
COVID-19
Cytokines
Growth factors
Hypertension
Hypothesis
Infections
Inflammation
Kinases
Nitric oxide
Phosphatase
Proteins
Pulmonary arteries
Pulmonary fibrosis
Severe acute respiratory syndrome coronavirus 2
Online AccessGet full text

Cover

More Information
Summary:Abstract Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1 receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall end-organ damage of this disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1076-1551
1528-3658
DOI:10.1186/s10020-020-00211-0